Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chesapeake takes over Pharmapost from Cegedim
The transaction was finalized on the 30 April 2012 and the other terms related to the transaction are confidential. Chesapeake CEO Mike Cheetham said, "This acquisition will enable
The transaction was finalized on the 30 April 2012 and the other terms related to the transaction are confidential. Chesapeake CEO Mike Cheetham said, "This acquisition will enable
The new ZAR300m ($38.3m) facility is in compliance with the international Pharmaceutical Inspection Convention and Pharmaceutical Co-operation Scheme Standards adopted by the South African Medicines Control Council. Adcock
Upon the completion of the sale, which is expected in the second quarter of 2012, the facility’s employees will become the employees of Perryman. Accellent president and CEO
The R&D center will focus on the development of science-based nutrition products for maternal and child nutrition and diabetes care. Abbott Nutrition Global R&D and Scientific Affairs divisional
The company has received FDA regulatory clearance for the randomized, multicenter, open-label, active-controlled trial of F-627. Generon CEO Yu-Liang Huang said, "This is the first innovative biologic drug
After the review of the supplemental new drug application (sNDA), which was submitted in June 2011, the FDA has announced the decision. Sunovion executive vice president and chief
The US District Court for the District of Delaware has found both the patents in a suit brought against Mylan Pharmaceuticals are valid. Genentech, OSI, (a US affiliate
Nevirapine 200mg tablets are AB rated to Viramune, which is marketed by Boehringer Ingelheim. The non-nucleoside reverse transcriptase inhibitor (NNRTI) is indicated for the treatment of HIV-1 infection
The change in endpoint mean pain score relative to baseline is the primary efficacy endpoint in the A0081242 study. In the double-blind, randomized withdrawal efficacy and safety study,
The randomized, placebo-controlled study, which will enroll approximately 100 patients who have triglyceride levels of 500mg/dL or higher, is designed to evaluate ISIS-APOCIIIRx as a monotherapy and in